Scm Sp. z o.o.
- Address
- lock Available on a paid plan
SCM Sp. z o.o. - Nephrology and Urology Research Center
SCM Sp. z o.o. is a clinical research center with established expertise in nephrology and urological oncology. The center demonstrates particular strength in conducting complex phase 3 trials evaluating novel therapeutic approaches for rare kidney diseases and advanced cancers, contributing to the development of innovative treatment options for patients with challenging medical conditions.
- Immunoglobulin A Nephropathy (IgAN) - Multiple trials investigating proteinuria reduction and renal function preservation
- Advanced urothelial cancer - Evaluation of antibody-drug conjugates and combination immunotherapy regimens
- Complicated urinary tract infections and acute pyelonephritis - Oral versus intravenous antibiotic efficacy studies
The center's research portfolio includes trials of cutting-edge therapies such as sparsentan, povetacicept, and mezagitamab for IgAN, demonstrating expertise in rare kidney disease management. In urological oncology, SCM participates in advanced studies combining zelenectide pevedotin with immunotherapy agents like pembrolizumab for locally advanced or metastatic disease. The center's capabilities extend to comparative effectiveness trials and long-term safety monitoring, with experience in blinded independent central review methodologies and complex biomarker assessments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Adamed Pharma S.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Scm Sp. z o.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL) | Biogen Idec Research Limited | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Buclizine Hydrochloride | 1 | Unknown | 2025-11-12 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.